You just read:

First and Only Immuno-Oncology Treatment, Imfinzi® (durvalumab), for Stage III, Unresectable Non-Small Cell Lung Cancer Now Approved in Canada

News provided by

AstraZeneca

May 09, 2018, 07:59 ET